Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 21, 2026
TickeronGET DAILY SIGNALS
AZN vs BMY: AstraZeneca Builds Earnings Momentum While Bristol Myers Faces Patent Pressures

AZN vs BMY: AstraZeneca Builds Earnings Momentum While Bristol Myers Faces Patent Pressures

Key Takeaways

  • Both AZN and BMY are large-cap pharmaceutical leaders, but their recent quarters point in different directions on earnings momentum.
  • AZN beat revenue and profit estimates, reaffirmed its full-year guidance, and raised its dividend, fueling a sharp rebound in its share price.
  • BMY topped revenue forecasts but saw adjusted earnings decline and lowered its earnings outlook, even as its newer "Growth Portfolio" kept growing at a double-digit pace.
  • Both companies face patent expirations on older blockbusters, but AstraZeneca's oncology-led pipeline is currently offsetting those pressures more cleanly than Bristol Myers' looming Eliquis cliff.
  • Tickeron AI Verdict: AZN — based on trend consistency, earnings momentum, and a catalyst-rich pipeline, the AI currently favors AstraZeneca over Bristol Myers Squibb.
  • For deeper coverage, explore AZN Major News and AZN Today's Price Move, as well as BMY Major News and BMY Today's Price Move.
  • To see which automated strategies are currently outperforming, explore the Trending AI Robots.

Why This Pharma Comparison Matters Now

Pharmaceutical stocks hold a unique spot in the market, delivering steady demand and recurring revenue while offering exposure to fast-growing areas like oncology. Comparing AZN and BMY feels especially relevant right now, as both navigate the challenge of replacing aging blockbusters losing patent protection—but from very different starting points. This analysis speaks to income investors focused on dividend reliability, growth investors tracking pipeline catalysts, and traders monitoring relative momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

AstraZeneca's Recent Results and Outlook

AstraZeneca focuses on oncology, biopharmaceuticals, and rare diseases. Recent quarterly results lifted sentiment after beating expectations, with revenue up roughly 7% on a constant-currency basis and core EPS rising about 19%, led by strong oncology contributions from Tagrisso, Imfinzi, Enhertu, and Calquence. These gains offset softness in older products like Farxiga and Brilinta now facing generics. The company reaffirmed full-year guidance and outlined a "Reshaping for Sustainable Growth" program aimed at roughly $1.5 billion in annual savings, much of which will go back into its pipeline of more than 180 projects. Management also plans to raise the 2026 dividend to $3.30 per share. These updates drove one of AZN's strongest single-day gains in a year, reversing earlier setbacks from clinical trial misses and shifting focus to an active catalyst calendar ahead.

Bristol Myers Squibb's Performance and Challenges

Bristol Myers Squibb operates across oncology, hematology, immunology, and cardiovascular areas. Its latest quarter showed revenue growth of about 7%, helped by a 12% rise in the newer Growth Portfolio including Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos, and Opdualag. Adjusted EPS, however, fell roughly 17% year over year amid higher acquired IPR&D charges and margin pressure. Management lifted full-year revenue guidance but cut earnings expectations due to those charges. The Legacy Portfolio, centered on Eliquis, faces a notable shift, with a projected $1.5 billion to $2 billion revenue step-down starting in 2027 as European exclusivity ends. Strong Eliquis demand has so far helped offset generic erosion elsewhere, and the stock has posted solid year-to-date gains on a roughly 4% dividend yield and attractive valuation for value investors.

Side-by-Side Assessment

The key difference lies in earnings direction. AZN is expanding both revenue and profits while holding guidance steady, supporting a more consistent upward trend. BMY, meanwhile, grows revenue but sees earnings pressure, with a guidance reduction and the large Eliquis patent expiry ahead. Valuation and income favor BMY, which trades at a lower P/E and higher yield, whereas AZN commands a premium multiple reflecting stronger growth prospects. Portfolio focus also diverges: AstraZeneca leans heavily into oncology and rare diseases with rapid growth potential but binary trial risks, while Bristol Myers offers more diversification yet remains tied to Eliquis for much of its legacy revenue. Recent price action shows AZN recovering more decisively after its earnings beat, while BMY has traded in a narrower range awaiting further catalysts.

Current AI Assessment

Looking at trend consistency, earnings revision direction, guidance stability, and near-term catalyst depth, the AI currently leans toward AZN over BMY. AstraZeneca combines rising earnings, steady outlook, a dividend hike, and a rich pipeline calendar for a more stable, positively trending profile. Bristol Myers delivers clear value and income appeal, yet declining earnings and the approaching Eliquis cliff add near-term uncertainty. This view remains probabilistic and tied to present conditions, which can evolve with new data.

How Tickeron’s Trending AI Robots Support My Analysis

One resource I check regularly for a more systematic angle is Tickeron’s Trending AI Robots. The page highlights automated strategies performing well in current markets, spanning different styles, timeframes, and tickers. It helps narrow down approaches that align with specific objectives while reflecting shifting conditions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BMY, AZN

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


BMY in downward trend: price dove below 50-day moving average on November 17, 2026

BMY moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend. In 32 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMY as a result. In 56 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.

The Moving Average Convergence Divergence Histogram (MACD) for BMY turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 27 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 55%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for BMY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.

Following a +1.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 175 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

BMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 151 of 217 cases where BMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.687) is normal, around the industry mean (-1.421). P/E Ratio (13.627) is within average values for comparable stocks, (21.700). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.041) settles around the average of (0.038) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -13%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -6%. OGN experienced the highest price growth at -0%, while SCLX experienced the biggest fall at -63%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 57%. For the same stocks of the Industry, the average monthly volume growth was 57% and the average quarterly volume growth was 34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 36
Price Growth Rating: 52
SMR Rating: 61
Profit Risk Rating: 61
Seasonality Score: 13 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceuticals products

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
Route 206 and Province Line Road
Phone
+1 609 252-4621
Employees
32500
Web
https://www.bms.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.